• Conference Proceeding

Budget impact of adding peginterferon beta-1A to the formulary for the treatment of relapsing forms of multiple sclerosis

Citation

Mauskopf, J. A., Graham, J., Fay-Azhar, M., & Kinter, E. (2015). Budget impact of adding peginterferon beta-1A to the formulary for the treatment of relapsing forms of multiple sclerosis. In [18], pp. A280–A281. .

Abstract

To estimate the budget impact of adding peginterferon beta-1a, a new interferon requiring injections only every two weeks for the treatment of relapsing forms of multiple sclerosis (MS), to a managed care formulary in the US.